Offer

- Suggestion of desing a methods of clinical studies in the field of viral infections after kidney transplantation, biocompatibility of dialysis membranes and peritoneal dialysis solutions, anticoagulation therapy during hemodialysis, and infectious

complications in hemodialysis population

- Evaluation of biocompatibility of dialysis membranes

- Cytomegalovirus and polyomavirus detection in blood or other tissues bas on molecular biology methods

- Assessment of cytomegalovirus antiviral drug resistance

Expertise

- Research activity is focused on infectious complications and their association with long-term results of kidney transplantation, and mainly with the incidence of graft rejection

- In a long run optimal mode of cytomegalovirus prevention has been evaluated in independent randomized trials with results being incorporated to the International Guidelines

- The possibilities of improvement of biocompatibility and anticoagulation therapy during dialysis are assessed in patients with end-stage kidney disease

Members

- Assoc. Prof. Tomáš Reischig, M.D., Ph.D. – Research Group Leader

- Mirko Bouda, M.D.

- Kateřina Černá, M.D., Ph.D.

- Assoc. Prof. Jaromír Eiselt, M.D., Ph.D.

- Prof. Ondřej Hes, M.D., Ph.D.

- Pavel Jindra, M.D., Ph.D.

- Martin Kačer, M.D., Ph.D.

- Lenka Karlíková, B.Sc.

- Lukáš Kielberger, M.D., Ph.D.

- Jan Klaboch, M.D., Ph.D.

- Jana Němcová, M.Sc., Ph.D.

- Ondrej Ondič, M.D.

- Prof. Sylvie Opatrná, M.D., Ph.D.

- Irena Prýcová

- Pavlína Richtrová, M.D., Ph.D.

- Prof. Tomáš Seeman, M.D., Ph.D.

- Daniela Šantová

- Tomáš Vaněček, Ph.D., M.Sc.

- Prof. Ondřej Viklický, M.D., Ph.D.

- Tomáš Vlas, M.Sc.

- Silvie Vondráková

Selected Publications

- Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O.: Pre-emptive valganciclovir therapy compared with valacyclovir prophylaxis for prevention of cytomegalovirus: 4-year results of a randomized trial in renal transplant recipients. J Am Soc Nephrol 2012, 23 (9): 1588–97

- Reischig T., Jindra P., Hes O., Bouda M., Kormunda S., Treska V.: Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009, 87 (3): 436–444

- Reischig T, Prucha M, Sedlackova L, Lysak D, Jindra P, Bouda M, Matejovic M.: Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Antivir Ther 2011, 16: 1227–1235

- Richtrova P, Rulcova K, Mares J, Reischig T.: Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. Artif Organs 2011, 35 (1): 83–88

- Reischig T.: Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy. Expert Rev Anti Infect Ther 2012, 10: 51–61

- Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M.: Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol 2015, 15 (2): 294–304

Are you interested in this expertise?

Please contact CPPT UK

Web: www.cppt.cuni.cz/

Mail: transfer@cuni.cz

Phone: +420 224 491 255

Experts and their department

Assoc. Prof. Tomáš Reischig, M.D., Ph.D.

Biomedical Center

Web: http://www.biomedic-plzen.cz/cz